Breast Cancer Therapeutics Market to be dominated by Targeted Therapy through 2027
The elevating number of
breast cancer patients and the development of cancer drugs are driving the
growth of the global breast cancer therapeutics market in the forecast period,
2023-2027.
According to TechSci Research
report, “Breast Cancer Therapeutics Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2017-2027”, the global breast cancer
therapeutics market is anticipated to witness a growth of steady CAGR in the
forecast period, 2023-2027. Cancer refers to the uncontrolled growth of certain
cells in the body that is being differentiated from normal cells. The outgrowth
of abnormal cells in the breast leads to breast cancer. These cells usually
form a tumour that can be felt as a lump, which is diagnosed by a mammogram.
Mutations in DNA can force normal breast cells to become cancerous cells.
The growing number of incidences
of breast cancer across the globe and the elevating need for therapeutics for
cancer treatment are primarily driving the breast cancer therapeutics market.
Along with this, extensive investments in research & development activities
and advancements in cancer biology and pharmacology that promotes drug
development are propelling the growth of the global head and neck cancer
diagnostics market. The government has introduced several reimbursements and
insurance policies that stimulate market growth. Also, the launch of numerous
diagnostic and screening programs to make people aware of the benefits of early
diagnosis of breast cancer is expected to drive the global breast cancer
therapeutics market in the upcoming years.
Continuous technological
upgradation in the therapeutics of breast cancer contributes to the growth of
the global breast cancer therapeutics market. Several product innovations are
aimed to treat breast cancer at the primary stage as well as the severe stage.
However, adverse side effects
associated with the use of breast cancer therapeutics methods and the high cost
of drugs may hamper the market growth in the forecast period.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Global
Breast Cancer Therapeutics Market"
https://www.techsciresearch.com/report/global-breast-cancer-therapeutics-market/10617.html
The global breast
cancer diagnostic market is segmented based on therapy, end user, company, and
regional distribution.
Based on the
therapy, the market is divided into chemotherapy, hormone therapy,
immunotherapy, targeted therapy, and others. Targeted therapy is expected to
account for the highest market share in the forecast period. Targeted therapy
possesses the versatility to combine with various other therapies coupled with
the emergence of a personalized approach to improve clinical outcomes. Recent
clinical analysis has widened the scope of targeted therapies to include multiple
molecules in targetable pathways. Moreover, developments in treatment for
metastatic hormone receptor-positive breast cancer have accelerated the
utilization of targeted therapies.
Based on the end
user, the market is divided into hospitals, specialty clinics, ambulatory
surgical centers, and others. Hospitals are anticipated to account for the
largest market share during the forecast period. Hospitals provide all needed
facilities to the patients to offer treatment from the renowned surgeon as well
as a positive environment for better results. With this, the hospital also
focuses on offering all kinds of advanced testing from advanced equipment and
novel technologies with accurate outputs.
Based on regional
analysis, the North American region is expected to dominate the global head and
neck cancer diagnostic market in the forecast period. The rising number of
breast cancer in the region is expected to escalate the demand for breast
cancer therapeutics. Besides this, the presence of leading market players and
favourable reimbursement scenarios for breast cancer treatment is expected to
support the market growth in the forecast period.
Key market
players operating in the global breast cancer therapeutics
market are:
- Novartis AG
- Pfizer Inc.
- Eli Lilly & Company
- Merck Co. & Inc.
- GlaxoSmithKline, Plc.
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Halozyme Inc.
- Eisai Co., Ltd.
- Fresenius Kabi AG
Download Sample Report@ https://www.techsciresearch.com/sample-report.aspx?cid=10617
Customers can also
request for 10% free customization on this report.
“Lifestyle-related risk
factors, including regular consumption of fast food, lack of exercise, and an
inadequate amount of sleep, can lead to chances of developing breast cancer.
The incidences of breast cancer and mortality rate associated with breast
cancer are significantly high. The emerging trend of introducing novel and
advanced therapies, including immunotherapies and targeted therapies in
developing as well as developed regions of the globe, are expected to stimulate
the global breast cancer therapeutics market till 2027” said Mr. Karan Chechi,
Research Director with TechSci Research, a research based global management
consulting firm.
“Breast Cancer Therapeutics
Market - Global Industry Size, Share, Trends, Opportunity and Forecast,
2017-2027 Segmented By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy,
Targeted Therapy, Others), By (Chemotherapy Drugs (Anthracyclines, Taxanes,
Antimetabolites, Others), By Hormone Therapy (Selective Estrogen Receptor
Modulators, Aromatase Inhibitors, Others), By Targeted Therapy (Monoclonal
Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others), By End User
(Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and By
Region”, has evaluated the future growth
potential of global breast cancer therapeutics market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global breast cancer therapeutics market.
Contact
Mr. Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]